TABLE 1.

Definitions used in the guidelines

Description/Term	Definition
	USMSTF 3	ESGE 4	BSG/ACPGBI/PHE 5
1–2 non‐advanced adenomas <10 mm in size	Low‐risk adenoma	Polyp not requiring surveillance	Premalignant polyp (not requiring surveillance)
Advanced adenoma/advanced adenomatous polyp	Adenoma ≥10 mm.	Polyp requiring surveillance	Adenoma ≥10 mm.
	2. Adenoma with high‐grade dysplasia.	1. Adenoma ≥10 mm.	2. Adenoma with high‐grade dysplasia.
	3. Adenoma with tubulovillous/villous histology.	2. Adenoma with high‐grade dysplasia.
Advanced neoplasia	Advanced adenoma CRC		This term has been used historically to describe the combination of advanced adenomas and colorectal cancers. It is considered outmoded because the serrated pathway is not included.
High‐risk adenoma	Advanced neoplasia ≥3 adenomas
Serrated polyp			Hyperplastic polyps (HPs), sessile serrated lesions (SSLs), SSLs with dysplasia (SSLd), traditional serrated adenomas (TSA) and mixed polyps.
Premalignant polyp			Serrated polyps and adenomatous polyps (excluding diminutive [1–5 mm] and rectal HPs)
Advanced serrated polyp			A serrated polyp ≥10 mm or with any grade of dysplasia.
Advanced colorectal polyp			The term includes both advanced serrated and advanced adenomatous polyps.

Abbreviations: ACPGBI, Association of Coloproctology of Great Britain and Ireland; BSG, British Society of Gastroenterology; CRC, colorectal cancer; ESGE, European Society of Gastrointestinal Endoscopy; PHE, Public Health England; USMSTF, US Multi‐Society Task Force.